Abstract
The ubiquitin-proteasome system (UPS) plays a vital role in maintaining protein homeostasis and regulating numerous cellular processes. The proteasome, a multi-protease complex, is the key component of the UPS and has been validated as a therapeutic target by the FDA's approval of bortezomib and carfilzomib. These proteasome inhibitor drugs have substantially improved outcomes in patients with hematological malignancies and are currently being investigated for other types of cancer as well as several other diseases. These approved proteasome inhibitors target the catalytic activity of both the constitutive proteasome and the immunoproteasome indiscriminately, and their inhibitory effects on the constitutive proteasome in normal cells are believed to contribute to unwanted side effects. In addition, selective immunoproteasome inhibition has been proposed to have unique effects on other diseases, including those involving aberrant immune function. Initially recognized for its role in the adaptive immune response, the immunoproteasome is often upregulated in disease states such as inflammatory diseases and cancer, suggesting functions beyond antigen presentation. In an effort to explore the immunoproteasome as a potential therapeutic target in these diseases, the development of immunoproteasome-specific inhibitors has become the focus of recent studies. Owing to considerable efforts by both academic and industry groups, immunoproteasome-selective inhibitors have now been identified and tested against several disease models. These inhibitors also provide a valuable set of chemical tools for investigating the biological function of the immunoproteasome. In this review, we will focus on the recent efforts towards the development of immunoproteasome-selective inhibitors.
Keywords: Immunoproteasome, proteasome inhibitors, molecular probes, autoimmune disorders, cancer, drug development.
Current Pharmaceutical Design
Title:Inhibitors of the Immunoproteasome: Current Status and Future Directions
Volume: 19 Issue: 22
Author(s): Zachary Miller, Lin Ao, Kyung Bo Kim and Wooin Lee
Affiliation:
Keywords: Immunoproteasome, proteasome inhibitors, molecular probes, autoimmune disorders, cancer, drug development.
Abstract: The ubiquitin-proteasome system (UPS) plays a vital role in maintaining protein homeostasis and regulating numerous cellular processes. The proteasome, a multi-protease complex, is the key component of the UPS and has been validated as a therapeutic target by the FDA's approval of bortezomib and carfilzomib. These proteasome inhibitor drugs have substantially improved outcomes in patients with hematological malignancies and are currently being investigated for other types of cancer as well as several other diseases. These approved proteasome inhibitors target the catalytic activity of both the constitutive proteasome and the immunoproteasome indiscriminately, and their inhibitory effects on the constitutive proteasome in normal cells are believed to contribute to unwanted side effects. In addition, selective immunoproteasome inhibition has been proposed to have unique effects on other diseases, including those involving aberrant immune function. Initially recognized for its role in the adaptive immune response, the immunoproteasome is often upregulated in disease states such as inflammatory diseases and cancer, suggesting functions beyond antigen presentation. In an effort to explore the immunoproteasome as a potential therapeutic target in these diseases, the development of immunoproteasome-specific inhibitors has become the focus of recent studies. Owing to considerable efforts by both academic and industry groups, immunoproteasome-selective inhibitors have now been identified and tested against several disease models. These inhibitors also provide a valuable set of chemical tools for investigating the biological function of the immunoproteasome. In this review, we will focus on the recent efforts towards the development of immunoproteasome-selective inhibitors.
Export Options
About this article
Cite this article as:
Miller Zachary, Ao Lin, Bo Kim Kyung and Lee Wooin, Inhibitors of the Immunoproteasome: Current Status and Future Directions, Current Pharmaceutical Design 2013; 19 (22) . https://dx.doi.org/10.2174/1381612811319220018
DOI https://dx.doi.org/10.2174/1381612811319220018 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: The Current World Health Organization Classification of the Myeloproliferative and Myelodysplastic/myeloproliferative Neoplasms and Correlation with Pertinent Targeted Therapy (Guest Editor: Cherie H. Dunphy)]
Current Cancer Therapy Reviews JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Anti-Cancer Agents in Medicinal Chemistry Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening
Current Cancer Drug Targets Non-squamous Tumors of the Oropharynx and Oral Cavity: CT and MR Imaging Findings with Clinical- Pathologic Correlation
Current Medical Imaging Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets Meet the Associate Editor
MicroRNA Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging A New Era of Immunotherapy in Prostate Cancer
Current Molecular Pharmacology Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Anti-cancer Effects of Curcumin on Head and Neck Cancers
Anti-Cancer Agents in Medicinal Chemistry Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma
Current Cancer Drug Targets ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies
Current Drug Delivery MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Targeting Notch as a Therapeutic Approach for Human Malignancies
Current Pharmaceutical Design